Abstract:Low molecular weight heparin (LMWH) has a structure similar to heparan sulfate, which exerts anti‑inflammatory effects via inhibiting elastase (Ela) activity. Release of Ela along the glomerular capillary wall may induce glomerular injury and proteinuria. The present study aimed to investigate the influence of LMWH on steroid‑sensitive nephrotic syndrome (SSNS) and the potential underlying mechanism. A total of 40 SSNS patients and 20 healthy controls were recruited. SSNS patients were treated with LMWH and prednisone simultaneously (LMWH+pred group) or with prednisone alone (pred group). Proteinuria, urinary glycosaminoglycans (GAGs), serum Ela and urinary creatinine levels were measured. The nephrotic period of SSNS was 15.93±5.78 days. The nephrotic period of SSNS in LMWH+pred group was significantly reduced compared with the pred group (14.13±4.56 vs. 18.63±6.49 days; P<0.05). At the follow‑up of the SSNS patients, there was no statistically significant difference in number of relapses between the LMWH+pred and pred groups. Proteinuria (2.51±0.97 g/24 h), urinary GAG levels (4.92±0.87 mg/mmol creatinine) and serum Ela levels (77.64±10.99 ng/l) were significantly greater in the nephrotic period of SSNS compared with the remission period (0.107±0.026 g/24 h, 1.53±0.27 mg/mmol Cr and 41.92±7.81 ng/l, respectively) and the healthy control group (0.098±0.027 g/24 h, 1.40±0.26 mg/mmol creatinine and 38.43±9.83 ng/l, respectively; P<0.05). During the remission period, urinary GAG and serum Ela levels in the LMWH+pred group were significantly reduced compared with the pred group (P<0.05), whereas proteinuria did not differ between these groups (P>0.05). Positive correlations were revealed between urinary GAG excretion and proteinuria (r=0.877; P<0.05), proteinuria and serum Ela levels (r=0.844; P<0.05) and serum Ela levels and urinary GAG excretion (r=0.881; P<0.05). The results of the present study indicated that elevated serum Ela levels may induce proteinuria by degrading GAGs in the glomerular basement membrane in children with SSNS. LMWH may benefit nephrotic remission of SSNS via inhibiting Ela.

Effects of Low Molecular Weight Heparin on Treatment of Nephrotic Syndrome

Comparison of Effects of Low Molecule Weight Heparin and Heparin on Refractory Nephrotic Syndrome

Preventive Effect of Low Molecuar Weight Heparin Sodiumon Renal Damages in Children with Henoch-Sch Nlein Purpura

Evaluation of the Anticoagulant Effect of Low-Molecular-weight Heparins Based on the Anti-Xa Level During Haemodialysis

Low Molecular Weight Heparin May Benefit Nephrotic Remission in Steroid-Sensitive Nephrotic Syndrome Via Inhibiting Elastase

Experimental study of low molecular weight heparin on renal protection in diabetic rats

Curative Effect of Sulfotanshinone United with Low Molecular Heparin in Primary Nephrosis Synthesis

Application of Low Molecular Weight Heparin in Induced Hemodialysis During Acute Renal Failure

Clinical Study on Low Molecular Weight Heparin in Treatment of Severe Hepatitis with Artificial Liver

Influence of low molecular weight heparin on the lipometabolism in hemodialysis patients

The Protective Effect of Low Molecular Weight Heparin on Early Nephropathy in Diabetic Rats

The Clinical Effect of Low Molecular Heparin on Maintenance of Hemodialysis

A Study on Atomization Inhalation of Low-molecular Heparin to Treat Hypercoagulabale State in Child Dropsical Nephritis Syndrome

Effect of Low Molecular Weight Heparin on Chinese Patients with Sepsis:A Meta-analysis

Inhibition Effect of Low Molecular Weight Heparin Combined with Dexamethasone on Catheter-related Thrombosis in Rabbit

Influence of low-molecular-weight heparin on PAI-1 in rats with immune complexes nephritis

Treatment of Primary Nephrotic Syndrome with Serious Edema and Oliguria with HAES-steril

Heparin calcium treated Henoch-Schönlein purpura nephritis in children through inhibiting hyperfibrinolysis

Research Progress of Low Molecular Weight Heparin

Comparison of low-molecular weight heparin with low-dose heparin in treating hemodialysis patients at high risk of bleeding

Clinical Study of Low Molecular Weight Heparin Therapy for Sepsis